Calamos Advisors’s RxSight RXST Stock Holding History

Calamos Advisors’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-53,932	Closed	-$2.67M	–	949
2024 Q3	$2.67M	Sell	53,932 -21,109	-28%	-$1.08M	0.01%	581
2024 Q2	$4.52M	Sell	75,041 -11,880	-14%	-$679K	0.02%	525
2024 Q1	$4.48M	Sell	86,921 -39,618	-31%	-$1.94M	0.02%	517
2023 Q4	$5.1M	Sell	126,539 -4,374	-3%	-$128K	0.02%	520
2023 Q3	$3.65M	Buy	130,913 +12,627	+11%	+$376K	0.02%	561
2023 Q2	$3.41M	Buy	+118,286	New	+$2.63M	0.02%	611

Other funds holding RXST

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Calamos Advisors's RXST Position: Q4 2024 in Review

Calamos Advisors sold out of RxSight (RXST) in Q4 2024, closing a stake of 53,932 shares — an estimated $2.67M sold.

Calamos Advisors first reported a position in RXST in Q2 2023 and held it in 6 quarters. The position peaked at $5.1M in Q4 2023. 212 funds tracked by Wall St. Rank hold RXST as of Q4 2024.

Calamos Advisors reported no remaining RxSight position as of Q4 2024 after selling out during the quarter.
Calamos Advisors sold 53,932 RxSight shares in Q4 2024, an estimated $2.67M.
Calamos Advisors first reported a position in RxSight in Q2 2023 and held it in 6 quarters.
Calamos Advisors's RxSight position peaked at $5.1M in Q4 2023.
212 funds tracked by Wall St. Rank held RxSight as of Q4 2024.

Based on Calamos Advisors's 13F filing for Q4 2024, filed 24 Jan 2025.